Neogene Therapeutics is a global, clinical-stage biotechnology company at the forefront of developing innovative treatments for solid cancers. They specialize in pioneering next-generation engineered T cell receptor (TCR) therapies that target neoantigens found in individual patients' tumors. Unlike traditional therapies, Neogene's tailored approach delivers personalized treatments based on the unique genetic makeup of each patient's cancer cells.

By identifying and selecting neoantigen-specific TCR genes, Neogene engineers patient-derived T cells to elicit strong and durable responses in various solid tumor indications. They also explore additional genetic modifications to enhance the effectiveness of engineered T cells. Neogene aims to revolutionize patient outcomes by broadening access to individualized T cell therapy for a wide range of cancers.

With an impressive team of TCR experts and industry veterans, they are committed to providing innovative therapies to cancer patients worldwide